Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
6.38
+0.25 (4.08%)
At close: Mar 9, 2026, 4:00 PM EDT
6.18
-0.20 (-3.13%)
After-hours: Mar 9, 2026, 5:25 PM EDT
Inventiva Revenue
Inventiva had revenue of 5.61M EUR in the half year ending June 30, 2025, a decrease of -15.28%. This brings the company's revenue in the last twelve months to 16.97M, down -10.36% year-over-year. In the year 2024, Inventiva had annual revenue of 14.09M, down -38.24%.
Revenue (ttm)
16.97M EUR
Revenue Growth
-10.36%
P/S Ratio
59.01
Revenue / Employee
202,024 EUR
Employees
84
Market Cap
1.18B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.09M | -8.73M | -38.24% |
| Dec 31, 2023 | 22.82M | 4.77M | 26.41% |
| Dec 31, 2022 | 18.05M | 9.55M | 112.35% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 362.27M |
| AbCellera Biologics | 75.13M |
| Septerna | 22.05M |
| Taysha Gene Therapies | 6.31M |
| Precigen | 6.31M |
| DBV Technologies | 5.50M |
| AtaiBeckley | 4.09M |
IVA News
- 20 days ago - Inventiva reports preliminary 2025¹ fiscal year financial results - GlobeNewsWire
- 4 weeks ago - Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 5 weeks ago - Biotech Inventiva's 50% surge shows investor optimism over liver disease drug - Reuters
- 7 weeks ago - Inventiva S.A. (IVA) Presents at 44th Annual J.P. - Seeking Alpha
- 3 months ago - Inventiva reports 2025 Third Quarter Financial Information¹ - GlobeNewsWire
- 4 months ago - Inventiva announces full exercise of Underwriters' Option, bringing proceeds of Offering to approximately $172.5M - GlobeNewsWire
- 4 months ago - Inventiva announces trading resumption of its ordinary shares on Euronext Paris - GlobeNewsWire
- 4 months ago - Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares - GlobeNewsWire